Ask sales for the Certificate of Analysis matched to the offered or supplied lot; it records the tests actually completed, applicable specifications, and reported results.
Review the matching batch COA for the analytical scope and results recorded for that lot.
Matching batch COA available.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Methionine / inositol / choline + B-vitamin multi-component preparation
Overview
Lipo-C (also called MIC Injection or MICC) is a lipotropic compounded injection containing methionine, inositol, choline, and B-vitamins (usually B12, with some formulations adding B6/B1). It is prepared by prescription compounding pharmacies and commonly marketed as an adjunct to weight-management programs and for liver metabolic support. These ingredients are believed to act together as methyl donors and fat-transport cofactors. Importantly, there is currently no well-designed randomized controlled trial demonstrating that the Lipo-C formulation itself — as a whole product — produces an independent, attributable weight-loss effect; the supportive evidence that exists comes from studies of individual ingredients (choline, inositol, carnitine, etc.) rather than from trials of the Lipo-C blend as a whole. Formulations are also not standardized across compounding pharmacies — ingredient lists and concentrations vary considerably between vendors (a common formula uses Methionine/Inositol/Choline Chloride/L-Carnitine/Thiamine HCl/Dexpanthenol at roughly 15/50/50/50/15/5 mg/mL, but this varies by supplier). The product is not FDA-approved for any indication. Vialdyne releases Lipo-C as a lyophilized peptide/vitamin blend (multiple independently characterized components) against a ≥ 99.0% HPLC main-peak specification, with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity, water content, residual solvents, and endotoxin. Sequence / identity confirmation is documented on the released lot.
Applications & buyer fit
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Supplied as a documented active in acetate counter-ion form by default; the buyer verifies current scheduling and compounding eligibility for the destination market.
Primary buyer fit: academic and contract research laboratories.
Specifications
Certificate of Analysis
Representative COA previews for Lipo-C; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.
Browse all published COAsRegulatory note
Research-use-only reference material; not for human or veterinary use.
Selected literature
Frequently asked questions
Identity is established component by component rather than as a single entity: each small-molecule component is confirmed by the appropriate HPLC and mass-spec identity check, the exact B-vitamin form is confirmed and stated, and the documented formulation is reported against the specification on the COA. Buyers should confirm each component and the B-vitamin form by COA or label before use.
B-12 occurs in several forms (cyanocobalamin, methylcobalamin, hydroxocobalamin, adenosylcobalamin) that are not interchangeable for all purposes, so the specific form in a given Lipo-C lot is stated on the COA rather than assumed. Vialdyne can configure the form on the preparation; specify the required form at order placement.